Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark E Cooper

Showing results (351-360 of 399) with videos related to

Pageof 40
Sort By:
Journal of the American Society of Nephrology : JASN|March 2, 2018
Lipoxins Regulate the Early Growth Response-1 Network and Reverse Diabetic Kidney DiseaseEoin P Brennan, Muthukumar Mohan, Aaron McClelland, et al.
Diabetes|February 17, 2018
RAGE Deletion Confers Renoprotection by Reducing Responsiveness to Transforming Growth Factor-β and Increasing Resistance to ApoptosisShinji Hagiwara, Karly Sourris, Mark Ziemann, et al.
The New England Journal of Medicine|June 13, 2020
New-Onset Diabetes in Covid-19Francesco Rubino, Stephanie A Amiel, Paul Zimmet, et al.
Clinical Kidney Journal|September 3, 2021
Erratum to: Effect of linagliptin versus placebo on cardiovascular and kidney outcomes in nephrotic-range proteinuria and type 2 diabetes (t2d): the carmelina randomised controlled trialChristoph Wanner, Mark E Cooper, Odd Erik Johansen, et al.
Clinical Science (London, England : 1979)|February 3, 2016
Mapping time-course mitochondrial adaptations in the kidney in experimental diabetesMelinda T Coughlan, Tuong-Vi Nguyen, Sally A Penfold, et al.
Diabetes Care|March 30, 2004
Renin angiotensin aldosterone system blockade and renal disease in patients with type 2 diabetes. An Asian perspective from the RENAAL StudyJuliana C N Chan, Nelson M S Wat, Wing-Yee So, et al.
Clinical Kidney Journal|February 10, 2021
Effect of linagliptin versus placebo on cardiovascular and kidney outcomes in nephrotic-range proteinuria and type 2 diabetes: the CARMELINA randomized controlled trialChristoph Wanner, Mark E Cooper, Odd Erik Johansen, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|November 20, 2012
Hemoglobin stability in patients with anemia, CKD, and type 2 diabetes: an analysis of the TREAT (Trial to Reduce Cardiovascular Events With Aranesp Therapy) placebo armHicham Skali, Julie Lin, Marc A Pfeffer, et al.
Nature Communications|March 16, 2018
Compression force sensing regulates integrin α<sub>IIb</sub>β<sub>3</sub> adhesive function on diabetic plateletsLining Ju, James D McFadyen, Saheb Al-Daher, et al.
Diabetes|June 21, 2024
The Role of Activator Protein-1 Complex in Diabetes-Associated Atherosclerosis: Insights From Single-Cell RNA SequencingAbdul Waheed Khan, Misbah Aziz, Karly C Sourris, et al.
Pageof 40

Showing results (351-360 of 399) with videos related to

Sort By:
Pageof 40
Journal of the American Society of Nephrology : JASN|March 2, 2018
Lipoxins Regulate the Early Growth Response-1 Network and Reverse Diabetic Kidney DiseaseEoin P Brennan, Muthukumar Mohan, Aaron McClelland, et al.
Diabetes|February 17, 2018
RAGE Deletion Confers Renoprotection by Reducing Responsiveness to Transforming Growth Factor-β and Increasing Resistance to ApoptosisShinji Hagiwara, Karly Sourris, Mark Ziemann, et al.
The New England Journal of Medicine|June 13, 2020
New-Onset Diabetes in Covid-19Francesco Rubino, Stephanie A Amiel, Paul Zimmet, et al.
Clinical Kidney Journal|September 3, 2021
Erratum to: Effect of linagliptin versus placebo on cardiovascular and kidney outcomes in nephrotic-range proteinuria and type 2 diabetes (t2d): the carmelina randomised controlled trialChristoph Wanner, Mark E Cooper, Odd Erik Johansen, et al.
Clinical Science (London, England : 1979)|February 3, 2016
Mapping time-course mitochondrial adaptations in the kidney in experimental diabetesMelinda T Coughlan, Tuong-Vi Nguyen, Sally A Penfold, et al.
Diabetes Care|March 30, 2004
Renin angiotensin aldosterone system blockade and renal disease in patients with type 2 diabetes. An Asian perspective from the RENAAL StudyJuliana C N Chan, Nelson M S Wat, Wing-Yee So, et al.
Clinical Kidney Journal|February 10, 2021
Effect of linagliptin versus placebo on cardiovascular and kidney outcomes in nephrotic-range proteinuria and type 2 diabetes: the CARMELINA randomized controlled trialChristoph Wanner, Mark E Cooper, Odd Erik Johansen, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|November 20, 2012
Hemoglobin stability in patients with anemia, CKD, and type 2 diabetes: an analysis of the TREAT (Trial to Reduce Cardiovascular Events With Aranesp Therapy) placebo armHicham Skali, Julie Lin, Marc A Pfeffer, et al.
Nature Communications|March 16, 2018
Compression force sensing regulates integrin α<sub>IIb</sub>β<sub>3</sub> adhesive function on diabetic plateletsLining Ju, James D McFadyen, Saheb Al-Daher, et al.
Diabetes|June 21, 2024
The Role of Activator Protein-1 Complex in Diabetes-Associated Atherosclerosis: Insights From Single-Cell RNA SequencingAbdul Waheed Khan, Misbah Aziz, Karly C Sourris, et al.
Pageof 40